```html

Intraocular Melanoma – A Comprehensive Medical Guide

Overview

Intraocular melanoma (also called uveal or choroidal melanoma) is a malignant tumor that arises from melanocytes—the pigment‑producing cells—within the eye. The most common site is the choroid, a vascular layer behind the retina, but the tumor can also develop in the ciliary body or the iris.

• Who it affects: Primarily adults between 40 and 80 years old; the median age at diagnosis is ~62 years.
• Gender: Slightly more common in men (≈55 % of cases).
• Race/ethnicity: Almost exclusively occurs in people with light skin, especially those of European ancestry; incidence among African‑American, Asian, and Hispanic populations is <1 % of that in whites.

In the United States, new cases are estimated at 2,500–3,000 per year (≈0.5 per 100,000 people) <sup>[1][2]</sup>. Worldwide, incidence varies from 0.2 to 0.5 per 100,000, with higher rates in northern latitudes where UV exposure is intense and skin pigmentation is lighter <sup>[3]</sup>. Although rare compared with cutaneous melanoma, intraocular melanoma accounts for >80 % of primary eye cancers.

Symptoms

Symptoms often develop slowly and may be unnoticed until the tumor is large enough to affect vision. Not every patient experiences all of them.

• Floaters: Small, dark specks or cobweb‑like shapes that drift across the visual field.
• Flashes of light: Brief bursts of light, especially in peripheral vision.
• Vision loss: Blurred or dim vision in one eye; may progress to a partial or complete loss of sight.
• Metamorphopsia: Distortion of straight lines or objects (e.g., a straight line appears wavy).
• Shadow or dark spot: A growing, often painless, dark area seen peripherally or centrally.
• Pupil changes: In iris melanoma, the pupil may become irregularly shaped or displaced.
• Eye pain or redness: Rare, but can occur if the tumor invades adjacent structures.
• Reduced peripheral vision: When the tumor is located near the edge of the retina.

If any of these changes are sudden, persistent, or worsening, an eye‑care professional should be consulted promptly.

Causes and Risk Factors

The exact cause of intraocular melanoma is not fully understood, but several factors increase risk.

Genetic and Biological Factors

• UV radiation: Cumulative exposure, especially to blue‑light wavelengths, may trigger DNA damage in melanocytes.
• Family history: Individuals with a first‑degree relative who has cutaneous or ocular melanoma have a 2–3 × higher risk.
• Genetic mutations: Alterations in the GNAQ and GNA11 genes are present in >80 % of uveal melanomas <sup>[4]</sup>.
• Light iris color: Blue or green irises contain fewer protective melanin pigments.

Environmental & Lifestyle Factors

• Outdoor occupations with prolonged sun exposure (e.g., farming, construction).
• Use of tanning beds—although the link is weaker than for skin melanoma.

Medical History

• Prior ocular lesions such as nevi (benign pigmented spots) that later undergo malignant transformation.
• Immune suppression (e.g., organ transplant recipients) may modestly increase risk.

Diagnosis

Early detection relies on a thorough eye examination followed by imaging and, when appropriate, tissue sampling.

Clinical Examination

• Dilated fundus exam: Ophthalmologists use special lenses and a slit‑lamp microscope to view the posterior segment.
• Indirect ophthalmoscopy: Provides a wide‑field view of the retina to locate tumors.

Imaging Modalities

• Ultrasound (B‑scan): Shows internal reflectivity and size; classic “hollow‑ground” appearance suggests melanoma.
• Optical Coherence Tomography (OCT): Provides high‑resolution cross‑sections of the retina and choroid.
• Fundus photography: Baseline documentation for monitoring growth.
• Fluorescein angiography & Indocyanine green angiography: Assess vascular patterns.
• Magnetic Resonance Imaging (MRI): Used to evaluate extra‑ocular extension or metastasis.

Biopsy (Rare)

Fine‑needle aspiration biopsy (FNAB) is reserved for ambiguous lesions or when molecular testing (e.g., BAP1 loss) will affect treatment decisions.

Systemic Staging

Because intraocular melanoma can spread hematogenously, a full work‑up is recommended:

• Chest, abdomen, and pelvis CT or MRI.
• Liver imaging (ultrasound, CT, or MRI) – the liver is the most common site of metastasis.
• Blood tests: liver function panel, LDH, and, in research settings, circulating tumor DNA.

Treatment Options

Treatment is individualized based on tumor size, location, patient age, visual potential, and systemic health.

Eye‑Preserving Therapies

• Plaque Brachytherapy: Radioactive seeds (Iodine‑125, Ruthenium‑106) are sutured to the sclera over the tumor for 3–7 days. Provides local control in >90 % of small‑to‑medium lesions <sup>[5]</sup>.
• External Beam Radiotherapy (EBRT): Proton beam or stereotactic radiosurgery (e.g., Gamma Knife) for tumors unsuitable for plaque.
• Transpupillary Thermotherapy (TTT): Infrared laser delivers heat to small (<3 mm) tumors; often adjunctive to brachytherapy.
• Local resection (Partial lamellar sclerouvectomy): Surgical removal for selected anterior tumors where vision can be preserved.

Enucleation (Eye Removal)

Reserved for large tumors (>15 mm base or thick >10 mm), those with total retinal detachment, or when vision is already lost. Modern orbital implants maintain cosmetic appearance.

Systemic Therapies for Metastatic Disease

• Immunotherapy: Checkpoint inhibitors (nivolumab, pembrolizumab) have shown modest response rates (~10–15 %).
• Targeted therapy: MEK inhibitors (selumetinib) for tumors with GNAQ/11 mutations—clinical trials report progression‑free survival benefit.
• Liver‑directed treatments: Hepatic artery chemo‑embolization (HACE), radio‑embolization, or isolated hepatic perfusion for liver‑dominant metastases.

Supportive & Lifestyle Measures

• Regular ophthalmic follow‑up (every 3–6 months for the first 5 years).
• Low‑vision rehabilitation when visual acuity is compromised.
• Psychological counseling—diagnosis of an eye cancer can be emotionally taxing.

Living with Intraocular Melanoma

Managing daily life after diagnosis focuses on vision preservation, monitoring for recurrence, and overall health.

Vision Care

• Use high‑contrast reading glasses or magnifiers.
• Adapt lighting—bright, glare‑free illumination reduces strain.
• Consider occupational therapy for tasks like driving or computer work.

Follow‑Up Schedule

• First year: every 3 months (exam, imaging, and liver function tests).
• Years 2–5: every 6 months.
• After 5 years: annually, unless new symptoms appear.

Emotional Well‑Being

• Join support groups (e.g., Melanoma Patient Network).
• Mindfulness, meditation, or counseling can reduce anxiety.

General Health

• Maintain a balanced diet rich in antioxidants (berries, leafy greens).
• Exercise regularly to improve circulation, which may aid ocular health.
• Avoid smoking—smoking worsens overall cancer outcomes.

Prevention

Because many risk factors are non‑modifiable (age, genetics), prevention centers on reducing UV‑related damage and early detection.

• UV protection: Wear wide‑brimmed hats and sunglasses with 100 % UV‑A/B blocking lenses every day.
• Regular eye exams: Baseline dilated examinations at age 40, then every 2–3 years, or sooner if risk factors exist.
• Monitor existing ocular nevi: Any change in size, colour, or shape warrants prompt evaluation.
• Skin‑eye health synergy: Adopt the same sun‑safety habits you use for skin cancer prevention.

Complications

If untreated or inadequately treated, intraocular melanoma can lead to serious sequelae.

• Vision loss: Permanent blindness in the affected eye (most common).
• Local invasion: Extension into the optic nerve, sclera, or orbit, making eye‑preserving surgery impossible.
• Liver metastasis: Occurs in 50–70 % of metastatic cases; often fatal within 12–24 months without treatment.
• Secondary glaucoma: Tumor‑related blockage of aqueous outflow.
• Orbital cellulitis or post‑enucleation socket infection: Rare but possible after surgery.

When to Seek Emergency Care

References

1. Mayo Clinic. “Uveal (ocular) melanoma.” Accessed May 2026. https://www.mayoclinic.org/diseases‑conditions/uveal‑melanoma
2. American Cancer Society. “Cancer Facts & Figures 2025.” https://www.cancer.org/research/cancer‑facts‑and‑figures
3. World Health Organization. “Global incidence of uveal melanoma.” WHO Cancer Report 2024.
4. Carvajal RD, et al. “Mutations in GNAQ and GNA11 in uveal melanoma.” New England Journal of Medicine. 2015;372: 102-111.
5. COMS (Collaborative Ocular Melanoma Study). “Radiation therapy for choroidal melanoma.” JAMA. 1998;279: 562‑568.

```